A bright future for women living with type 1 diabetes

7 July 2025

Pregnancy

CamAPS FX was designed with the demanding pregnancy glucose targets in mind

We are in a new era of diabetes management, where advances in technology are helping reduce the risks associated with type 1 diabetes. These developments are making healthy pregnancies and positive outcomes more achievable than ever before.

Innovation in closed-loop technology

The app powering myLoop Automated Insulin Delivery (AID) system, CamAPS FX, was designed with pregnancy glucose targets in mind. CamAPS FX is indicated for use in pregnancy.

Women using the CamAPS FX app report easier glucose management during their pregnancies. The possibility to set a Personal Glucose Target (PGT) within the pregnancy target range provided them with much-needed flexibility.¹

‘‘Before I was on the hybrid closed-loop, every couple of weeks I had to keep changing all my basal rates to try and keep up, whereas the algorithm just automatically does it. It just takes a lot off you; even the mental side of just constantly viewing the data.¹ ’’

AiDAPT study participant (010)

Clinical and real-world evidence

The recently published AiDAPT study supports the safety and efficacy of the CamAPS FX algorithm². In this randomised controlled trial, the 61 women using CamAPS FX during pregnancy showed significant improvements in maternal glucose levels compared to the standard insulin delivery (MDI or insulin pump) with CGM group with 63 participants.

+10.5 % more time spent in the pregnancy range 3.5-7.8 mmol/L
Achieved pregnancy HbA1c target of 6.0 % (42 mmol/mol), a 0.3 % reduction compared to the standard insulin delivery group
No increased risk of mild or severe hypoglycaemia

Read all study insights here

Encouragement from healthcare systems

Many healthcare systems in Europe already offer CGMs to people living with type 1 diabetes. Robust clinical data supports the use of CGMs during pregnancy in women living with type 1 diabetes. Outcomes from the CONCEPTT³ randomised trial found that CGM resulted in more women achieving their pregnancy glycaemic targets, as well as a reduction in neonatal intensive care admissions, neonatal hypoglycaemia, and babies born large for gestational age (LGA).

‘‘During my first pregnancy eight years ago I used capillary testing, setting alarms every two hours through the night. I stopped driving and made sure I was accompanied overnight throughout the pregnancy for fear of a catastrophic hypo.’’

Nina Willer, living with type 1 diabetes and mother of two

In the meantime, more and more national guidelines recommend HCL as the standard of care for women with type 1 diabetes planning to become pregnant.⁴

The future is bright!

Diabetes technology is breaking barriers. Such advancements also include the management of type 1 diabetes during pregnancy. Today, women can manage their diabetes with an AID system not only at the planning stage, but also during and after pregnancy.

The latest results of the AiDAPT answered a very important question: how does a type 1 diabetes pregnancy look when women achieve pregnancy glycaemic targets thanks to the use of CamAPS FX hybrid closed-loop technology? The future is bright!

Discover myLoop